Overview

Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscesses

Status:
Completed
Trial end date:
2011-08-15
Target enrollment:
Participant gender:
Summary
The study is contemplating the antibiotic therapy of intraabdominal abscesses. These abscesses are a serious problem in surgical practice. Associated pathophysiologic effects as for example peritonitis may become life threatening or may lead to extended periods of morbidity with prolonged hospitalization. The objective of the sudy is to evaluate whether the combination of Moxifloxacin and Metronidazole is equivalent to Piperacillin / Tazobactam with regard to clinical outcome and eradication of aerobe and anaerobe pathogens in patients with intra-abdominal abscesses.
Phase:
Phase 3
Details
Lead Sponsor:
Hannover Medical School
Collaborator:
Bayer
Treatments:
Fluoroquinolones
Metronidazole
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Penicillanic Acid
Piperacillin
Piperacillin, Tazobactam Drug Combination
Tazobactam